Why IMU is a multi multi bagger, page-20580

Hi @fourdollars

Thank you for your post and for considering me in your thoughts.

The facts as I see it remain, Her Vaxx was very successful for late stage gastric cancer patients in its Phase 2 Trial, in extending life beyond the standard of care in a safe environment (please read my earlier post(s).I cannot ever remember stating there was going to be catalysts for the drug in the ensuing two years. From my understanding the vaccine is being positioned to either out license, partner with a third party or be sold.

Imugene as you are aware,(i.e., if you read their newsletters,) are prioritising their flagship candidate Vaxinia atm. I do however look forward to further announcements of a commercial nature pertaining to Her Vaxx in the coming six months. In the interim I don't know but would assume there is no doubt NDA's, privacy and confidentiality agreements or even MOA's in place restricting what can or cannot be disclosed pertaining to what promises to be a sound commercial outcome this novel vaccine.

Can't wait to see this excellent drug with so much promise reaching out to assist patients in need in years to come.

WMHB

DYOR Opinions only